News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Has Aerie (AERI) Put The 'Binary Boogeyman' To Bed With Roclatan Phase III Data?



5/26/2017 5:53:49 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Aerie Pharmaceuticals Inc (NASDAQ: AERI) shares were seen up over 29 percent Thursday after the company reported positive Phase III trial data on its glaucoma treatment candidate, Roclatan. According to the company, Roclatan achieved the primary efficacy endpoint in demonstrating superiority over both latanoprost and Rhopressa.

Read at News Release


comments powered by Disqus
 
 
Glaucoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES